Targeted therapy is a cancer treatment that restricts the growth and spread of cancer by targeting the specific genes and proteins that are responsible for the growth, progression, and spread of cancerous growth. Targeted cell therapy is the foundation of precision medicine and can be categorized into two types. One type of target therapy involves the use of small molecules (drugs), which can easily enter cells where they stop cancerous growth. The other type involves the use of larger molecules (monoclonal antibodies), which are unable to enter cells and therefore affect targets outside of cells or targets on cells’ surface.
Know anyone building innovative solutions that belong in this 'Targeted Therapeutics'?
The 2023 Precision Oncology Summit: Personalizing Treatment to Improve Patient Outcomes is an oncology conference featuring leading experts in the field of precision oncology who will provide a comprehensive overview of the implications of actionable molecular alterations across common malignancies. Expert faculty will discuss and analyze the latest scientific findings and practice-changing advances in precision oncology, including the key abstracts relevant to precision oncology presented at the 2023 ASCO Annual Meeting in June 2023.This conference will augment healthcare providers’ foundation of knowledge and clinical competence in several areas, including Integrating different platforms available for testing of actionable molecular alterations for identification of targeted therapy options, Current and evolving paradigms in precision oncology approach for management of common malignancies and Trends, challenges, controversies, and cost-considerations of precision oncology approaches and targeted therapies.
Over time, gene therapy has evolved into a promising treatment option for a number of diseases, including cancers, rare inherited disorders and certain infectious diseases. In fact, gene therapies are …
Global Summit on Liver Diseases and Therapeutics (GSLDT-23), which is scheduled to take place on the July 28th 2023 in Zurich, Switzerland organized by Institute for Technical and Academic Research (ITAR) will offer researchers, delegates and scholars an incredible chance to interact with each other and share their experience and knowledge of technology application. In order for true progress to be achieved in Global Summit on Liver Diseases and Therapeutics , it simply isn't enough for professionals in the field to gather at boilerplate events that have been designed as part of a "one-size-fits-all" approach to to academic event organizing.
Antibody Engineering 2023 Online delves into the latest in antibody engineering and antibody-based therapeutics & a meeting place for experts working within engineering, computational tools and antibody-based therapeutics. The 2023 event brings together a panel of prominent leaders and scientists, sharing new case studies, innovative data and industry outlook. Benefits to Attending are Hear from and meet with the leading figures in the antibody, ADC and bispecific engineering antibody-based therapeutics; offering in-depth presentations and new inspiring ideas to advance your research, Engage in in-depth panel discussions, roundtables and workshops brining together like-minded experts to address the pressing challenges & opportunities of the market and Explore case studies including antibody gene therapy and developing antibody therapies aiding the treatment of Covid-19. Major event features includes Networking & knowledge-sharing is at the heart of what we do. Alongside the innovative programme, attendees can engage in a variety of event features and make the most of participation in a range of virtual experiences.
The 2nd Next Generation RNA Therapeutics Summit returns as the first and only industry-dedicated forum solely focused on next generation RNA therapeutics and vaccines that are more targeted, and efficacious, with reduced off targets than first generation RNA therapies to accelerate their therapeutic and commercial potential.
Expect exclusive data from KOLs on the most recent developments in circRNAs, saRNAs, eRNAs and tRNAs therapies.
Join 100+ thought leaders from the likes of Pfizer, Orna Therapeutics, Laronde, Replicate Bioscience and BioNTech to stay ahead of the curve and maximize the full therapeutic potential of next generation RNA modalities to gain clinical proof concept and reach patients in need.
With the recent announcement of Fate Therapeutic's preclinical and clinical success with iPSC-derived candidates, the race to streamline iPSC process development is on.
Join the 2nd iPSC Manufacturing Summit, the industry-defining forum for technical leaders within manufacturing, process development, quality and regulations. Showcasing in-depth data-driven case studies to accelerate the development of high-quality iPSC lines, with optimized differentiation and automated scale up.
This meeting boasts the unique opportunity to discuss the procedural barriers preventing iPSC-derived therapies reaching the clinic, tackling all your CMC and regulatory needs. Take home creative approaches to unify your manufacturing process and advance the quality and quantity of your product for successful commercialization.
Uniting leading CMC, Regulatory, QC, Analytical and Process Development experts, the 4th Annual Gene Analytical Development Europe Summit is the industry's definitive and only meeting focused on tackling the greatest analytical development challenges in the context of gene therapy drug development.
Hear from the likes of AstraZeneca, MHRA, Gyroscope, REGENXBIO, Biogen, Spark Therapeutics, and more across three days and two tracks of in-depth case studies, interactive panel discussions, dedicated Q and A time, and highly appraised networking opportunities to meet and learn from the leaders of this pioneering field.
Don't miss the opportunity to network with 80+ analytical experts to overcome your analytical challenges encountered in every stage of the gene therapy development life cycle.
From screening technologies directing identification, prediction, and validation of neoantigens; to translating personalised medicine to the clinic, the 6th Annual Neoantigen Summit Europe returns to Amsterdam, as the only summit in Europe dedicated to advancing exclusive tumour antigen discovery and personalised therapeutic development within the world of immunotherapy.
Devoted to the successful discovery, translation, and development of individualised neoantigen vaccines and cell immunotherapies, join 150+ experts at the forum, as they navigate validation of neoantigen targets and review methodologies/technologies to support with translating neoantigen-based studies effectively to the clinic.
Join is in 2023 for the latest preclinical updates, and evaluate the hottest clinical data from leading biotechs, such as Nouscom, Gritstone, and BioNTech, CurVac.
Spearheading Safe, Potent, Scalable Innate Immune Therapies Spanning NK, iNKT, Gamma Delta, and Macrophages. Realize Lasting Clinical Response with Next-Generation Engineering to Provide Off-the-Shelf Delivery for More Patients, Globally
Dedicated to driving cost-effective, efficacious, safe, durable, scalable, and globally accessible allogeneic, cell-based, and engager therapies, the 8th Innate Killer Summit returns to cement your end-to-end education in innate immune therapeutics. Your industry-defining Innate Killer Summit brings crucial insights for everyone on your team, spanning preclinical development, clinical translation, CMC, process development, and clinical scale manufacturing, this is the definitive meeting to drive concept to commercial success of emerging innate immune therapies.
Welcome to the 4rd Annual RNAi - Based Therapeutics Summit: Unleash the Potential of siRNA Therapies in Extrahepatic Tissues
Bringing together both technical and strategic expertise sharing case studies with actionable insights, the 4th RNAi-Based Therapeutics Summit returns to Boston to address the most pressing challenges preventing the widespread adoption of RNAi therapies and tackling targets beyond the liver.
With 20+ pioneering speakers from large pharma, innovative biotech, and KOLs of academia, join us to discuss novel delivery modalities, next-generation chemistries, clinical updates, scaling up. and more.
With strong effectiveness profiles and 20 years of FDA approval, kinase inhibitors have revolutionized oncology treatment. The success of current kinase inhibitor classes is nevertheless constrained by rising resistance and security concerns.
The 2nd Next Generation Kinase Inhibitors Summit is the only industry-focused conference devoted to using novel kinase biology in drug development and innovating current programs to produce the next generation of kinase inhibitor drugs that can demonstrate effective and long-lasting clinical responses in oncology and other fields.
The past twelve months have seen an unprecedented level of excitement, investment, and progression within the gene therapy for muscular disorders field. As the industry endeavours to move gene therapy treatment through the preclinical and clinical pipeline, in context of reducing toxicity and increasing efficacy, attending the 3rd Annual Gene Therapy for Muscular Disorders Summit has never been so crucial.
This year's summit will return to Boston to reunite 100+ leading experts in biotech, pharma and academia to continue to develop strategies to deliver safer and more effective gene therapies to muscle cells.
This summit will encompass all aspects of preclinical development and highlight the obstacles in clinical trials, enabling you to address and overcome these challenges.
A high proportion of new drug candidates never reach market due to poor solubility, which limits their potential for absorption. As such, the solubility and permeability of an active pharmaceutical ingredient (API) are the driving forces behind bioavailability. In order to avoid development challenges and delays, it is critical to fully explore these parameters when developing formulations to enhance and maximise oral bioavailability. Lipid-based drug delivery systems offer a way to effectively deliver poorly soluble or bioavailable drugs in both preclinical and human studies. The physicochemical characteristics of the API determine if lipid delivery is an appropriate approach for dosage form design.
The assurance cookie is found and is being filtered in Google Analytics.
These cookies are used to collect information about how you interact
with our website and allow us to remember you. We use this
information in order to improve and customize your browsing
experience, and for analytics and metrics about our visitors both on
this website and other media. To find out more about the cookies we
use, see our